Evaluation of the market potential of the asset gained through the acquisition
A global pharmaceutical company wished to evaluate the market value of an asset obtained by acquiring a mid-cap company. The new class of drug showed the potential in targeting multiple tumors in combination with their in-house immune checkpoint inhibitor (CPI). The assessment formed the basis of their decision to either retain or divest the product later.